Welcome to our dedicated page for Nanovibronix news (Ticker: NAOV), a resource for investors and traders seeking the latest updates and insights on Nanovibronix stock.
NanoVibronix Inc., now ENvue Medical Inc., reports medical-technology developments centered on enteral access, non-invasive therapy and commercialization under the FEED ticker following its completed name and symbol change from NAOV. The company’s ENvue™ Navigation Platform is a minimally invasive electromagnetic navigation system for assisting clinicians with feeding-tube placement in the gastrointestinal tract, with FDA 510(k) clearance for adult use and real-time bedside visualization.
Recurring updates include ENFit syringe launches and distribution, UroShield® reimbursement and market-access developments, patent activity for feeding-tube navigation and visualization, and commercial leadership changes. The company also describes acoustic-based therapeutic technologies, including PainShield® and UroShield®, that use proprietary low-intensity surface acoustic wave technology for pain, bacterial colonization and biofilm-related applications.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
NanoVibronix, Inc (NASDAQ: NAOV) released a shareholder letter detailing the company's performance in 2022 and its prospects for 2023. Despite challenges, including regulatory delays that caused a revenue drop of approximately $900,000, the company has made strategic advancements, such as transitioning to a more effective distributor and reintroducing PainShield Plus. Positive clinical evaluations highlight the effectiveness of UroShield, showing improved patient outcomes and satisfaction. The company is focused on increasing distribution, particularly in VA hospitals, and expanding its international presence. Financially, the company ended 2022 with $2.7 million in cash and invested $2.4 million in inventory to support future sales. NanoVibronix emphasizes a strong potential for growth in 2023, with ongoing product studies and new contracts expected to drive revenue.